Anaplastic Large Cell Lymphoma (systemic)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-ALCL |
|---|---|
| Type | Disease |
| Aliases | ALCLAnaplastic Large Cell Lymphoma, SystemicsALCLАнапластична великоклітинна лімфома (системна) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9714/3 |
|---|---|
| icd_10 | C84.6 |
| who_classification | Mature T-cell neoplasms — Anaplastic large cell lymphoma per WHO 5th ed. |
Notes
Three distinct entities under "ALCL" umbrella: systemic ALCL ALK+, systemic ALCL ALK-, primary cutaneous ALCL (separate disease, indolent). Breast-implant-associated ALCL is fourth distinct WHO 5th-ed entity (rare; treatment surgical + adjuvant). All CD30+ → brentuximab-CHP (ECHELON-2) preferred over CHOP for systemic disease.
Used By
Actionability
BMA-ALK-FUSION-ALCL- ALK-positive ALCL (typically NPM1-ALK t(2;5)) is generally cured by CHOP-based regimens w...BMA-CD30-ALCL- CD30 expression is a defining feature of anaplastic large-cell lymphoma (sALCL); brentuxi...
Algorithms
ALGO-ALCL-1L- ALGO-ALCL-1LALGO-ALCL-2L- ALGO-ALCL-2L
Disease
DIS-AITL- Angioimmunoblastic T-Cell Lymphoma / Nodal TFH-cell lymphomaDIS-PTCL-NOS- Peripheral T-Cell Lymphoma, Not Otherwise Specified
Indication
IND-ALCL-2L-BENDAMUSTINE- IND-ALCL-2L-BENDAMUSTINEIND-ALCL-2L-BRENTUXIMAB-MONO- IND-ALCL-2L-BRENTUXIMAB-MONOIND-ALCL-2L-CRIZOTINIB-ALKPOS- IND-ALCL-2L-CRIZOTINIB-ALKPOSIND-ALCL-MAINTENANCE-BV-POST-ASCT- IND-ALCL-MAINTENANCE-BV-POST-ASCTIND-TCELL-1L-CHP-BV- IND-TCELL-1L-CHP-BV
Questionnaires
QUEST-ALCL-1L-STUB- Anaplastic Large Cell Lymphoma, Systemic — first line
Red flag
RF-ALCL-FRAILTY-AGE- Frailty profile precluding full-dose CHP-Bv in ALCL: ECOG ≥3, OR (age ≥75 with G8 ≤14), O...RF-ALCL-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating CHP-Bv /...RF-ALCL-ORGAN-DYSFUNCTION- Baseline organ dysfunction precluding standard CHOP/CHP-Bv doses in ALCL: LVEF <50% (anth...RF-ALCL-TRANSFORMATION-PROGRESSION- ALCL primary-refractory disease (no CR after 4 cycles CHP-Bv) OR early relapse <12 months...RF-TCELL-CD30-POSITIVE- Reported CD30 expression in T-cell lymphoma; a targeting signal requiring confirmed patho...
Sources
SRC-ECHELON-2-HORWITZ-2019- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHEL...SRC-ESMO-PTCL-2024- ESMO Clinical Practice Guideline on Peripheral T-cell Lymphomas